Consensus of overarching considerations that will inform the final document Because new data are rapidly accruing, this WHO document may need to be updated in the future when more information is available. To avoid restricting future development, this WHO document should include statements on the need for case-by-case considerations and benefit/risk evaluation. It is important that NRAs are engaged early on in vaccine development and evaluation to ensure the optimal progress of clinical trials of mRNA vaccines.